Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study

• DOI: 10.1007/s12325-021-01649-2
• Publication Date: 2021-03-11T13:02:55Z
• Authors: Markus Ketteler; Kristina Chen; Elvira O. Gosmanova; James Signorovitch; Fan Mu; Joshua A. Young; Nicole Sherry; Lars Rejnmark
• Keywords: Nephrocalcinosis; Hypoparathyroidism

Chronic hypoparathyroidism managed with conventional treatment, comprising oral administration of calcium and active vitamin D, has been associated renal complications, including nephrolithiasis nephrocalcinosis. Further larger-scale studies are needed to examine these risks. This study evaluated the risk nephrocalcinosis in patients chronic hypoparathyroidism. A retrospective cohort using a care claims database United States from January 2007 June 2017. Included were those (excluding receiving parathyroid hormone) randomly selected without over maximum 5-year follow-up. The main outcome measures nephrolithiasis, identified by diagnosis codes or procedure for removing kidney stones, nephrocalcinosis, codes. analyses included 8097 adult 40,485 After excluding at baseline, 8051 40,466 During 5 years follow-up, had significantly increased Kaplan–Meier analysis compared (both P < 0.001). In adjusted analyses, was higher risks (hazard ratio [HR], 1.81; 95% confidence interval [CI] 1.60–2.04) (HR, 6.94; CI 4.41–10.92). sensitivity restricted least one imaging examination showed that 2.6% (n = 59) 0.5% 20) (ratio, 5.5; 0.001) developed large statistically significant clinically meaningful who have do not